Special Issue "Identification and Validation of New Biomarkers to Help the Creation of Clinical Diagnostics in Autoimmune and Cancer Diseases"
Deadline for manuscript submissions: 30 November 2023 | Viewed by 4756
Interests: diagnostics; immunology; biomarkers; autoimmune diseases; infectious diseases; immunotherapy; validation; assay development
Special Issues, Collections and Topics in MDPI journals
Special Issue in Healthcare: Maternal Nutrition on Neonatal Health
The identification of biomarkers in patients with immunological diseases, including cancer and autoimmune diseases, is critical to prevent disease progression (stopping disease evolution), predicting the prognosis (correlation between the biomarker and clinical outcomes), targeting the appropriate therapeutic drugs and personalized medicine (response to treatment), and clinical decision-making processes involved in diagnosis and assessment of disease activity (ability to reflect changes in clinical status). Measurement of biomarker proteins and signature protein expression specific to the disease and biological samples (blood and/or tissue) help to understand the mechanisms involved in the pathogenesis of these disorders. For cancer, immune-monitoring assays for immunosuppressive factors that prevent an effective antitumor immune response in tumor tissues and peripheral blood are necessary to improve immunotherapy strategies. New assays should be optimized to obtain the optimal accuracy of analyte in various samples (matrix effect and inhibitory agents), as well as an appropriate balance of sensitivity and specificity before being implanted in a clinical diagnostic laboratory. Additional prerequisites of biomarker validation are reliability, accuracy, and reproducibility. However, the validation of an assay measuring biomarker(s) specific to a disease or clinical outcomes is often lacking in products and reagents for biomedical research.
This Special Issue aims to concentrate on and describe the current development of research on new assays to identify and validate new biomarkers to enhance the creation of clinical diagnostics in autoimmune and cancer diseases.
Dr. Veronique Demers-Mathieu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- autoimmune diseases
- assay development
- signature protein expression